NCT07292376
Implementing VTE Prevention in Ambulatory Cancer Care
Enrolling by Invitation
NAAges 18+InterventionalUniversity of VermontInvestigator-initiated
~25 participants
Updated 2025-12-18 on ClinicalTrials.gov
What's tested:Clinical program
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Documented VTE risk assessment
Measured over 30 days after new patient appointment
Conditions
Where it's being run
1 sites across 1 statesVermont1
Study leadership
- Karlyn Martin, MD · PRINCIPAL_INVESTIGATOR · University of Vermont
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Clinicians: practicing oncologist at study clinic site (UVMMC)
Patients: diagnosis of cancer; starting new systemic cancer-directed therapy at a study clinic site under the direction of the enrolled clinician
Exclusion
none
What this trial measures
- Documented VTE risk assessment30 days after new patient appointment
Proportion of new patients who have documented VTE risk assessment